Immune Pharmaceuticals Inc (fka IMNPQ)

[itsabouttime]

BREAKING DOWN 'SEC Form NT 10-Q'
The form 10-Q is required to be filed within 45 days following the end of each of a company's first three fiscal quarters. If the 10-Q cannot be filed in a timely manner, the company must file a Form 10-QT with the commission. A very common reason for an NT 10-Q is a merger or acquisition, which prevents results from being incorporated in time for the filing. The SEC provides for "unreasonable effort and expense", with explanation, as part of the application for relief.

May be related to this:

Immune is also moving forward with forming three private companies separate from the development of bertilimumab, focusing on Immuno-Oncology, Dermatology, and Pain & Neurology respectively. The Immuno-Oncology subsidiary will focus on Ceplene, which recently received guidance from the FDA for a pivotal phase 3 Overall Survival study in remission maintenance for Acute Myeloid Leukemia, and novel bispecific antibodies targeting immune check points and other novel targets. The Dermatology subsidiary will focus on the application of nanotechnology to dermatology. The lead program is a topical cyclosporine for the treatment of psoriasis and atopic dermatitis. The Pain and Neurology subsidiary will focus on AmiKet(r) for the treatment of peripheral neuropathic pain with the subsidiarys new management looking at complementary assets.

Read more: SEC Form NT 10-Q Definition | Investopedia http://www.investopedia.com/terms/s/sec-form-nt-10-q.asp#ixzz4QH7xDBUl
Follow us: Investopedia on Facebook